Ann: Landmark Partnership for Fiji Kava to Enter Chinese Market, page-165

Intriguing to note that the pro-rata quarterly revenue associated with the PuMate contract alone (minimum $8m over three years) is roughly 5-6 times (500%-600%) the most recent quarterly revenue. I think this may perhaps better put into perspective the magnitude of this deal, especially when the 50% increases in quarterly revenue have been well received previously.

There has been an ongoing discussion in some of these forums regarding a CR - presumably to scale up production, etc - but has anybody got an insight as to whether some of these contracts have been anticipated (or at the least the potential for a significant increase in product requirements) in the "product manufacturing and operating costs" per previous 4C announcements?